Prostat Kanseri ve Hemşirelik Bakımı
Özet
Prostat kanseri, özellikle ileri yaş erkeklerde en sık görülen kanser türlerinden biridir ve kanser kaynaklı ölümlerde üst sıralarda yer aldığından hem dünyada hem ülkemizde önemli bir sağlık sorunu olarak kabul edilmektedir. Kanserin evresine göre birçok tedavi seçeneği bulunmaktadır. Hem hastalığın kendisi hem tedavi modaliteleri hastanın yaşamını ve iyi oluşunu birçok yönden etkilemektedir. Erken tanı ve etkin tedavi süreçleri kadar, hastalara sunulan bakım da büyük önem taşımaktadır. Bu süreçte hemşireler, hastaların fiziksel, psikolojik ve sosyal gereksinimlerini göz önünde bulundurarak bütüncül ve bireyselleştirilmiş bakım planları geliştirmelidir. Etkili semptom yönetimi, hastaların konforunu artırırken, ailelerin de dahil edildiği doğru ve anlaşılır hasta eğitimi ile hastaların tedaviye uyumları desteklenmelidir.
Prostat kanseriyle yaşayan bireylerin yaşam kalitesini artırabilmek için hemşirelik bakımının güncel bilimsel veriler doğrultusunda şekillendirilmesi gerekmektedir. Bu doğrultuda, kanıta dayalı uygulamaların benimsenmesi, bakım kalitesini artırarak hastaların sağlık sürecinde daha iyi sonuçlar elde etmelerini sağlayacaktır.
Prostate cancer is one of the most common types of cancer, especially in older men, and is considered an important health problem both in the world and in our country, as it is among the top causes of cancer-related deaths. There are many treatment options depending on the stage of cancer. Both the disease itself and treatment modalities affect the patient's life and well-being in many ways. The care provided to patients is as important as early diagnosis and effective treatment processes. In this process, nurses should develop holistic and individualized care plans, taking into account the physical, psychological and social needs of patients. While effective symptom management increases patients' comfort, patients' compliance with treatment should be supported with accurate and understandable patient education, including families.
In order to improve the quality of life of individuals living with prostate cancer, nursing care must be shaped in line with current scientific data. In this regard, adopting evidence-based practices will increase the quality of care and enable patients to achieve better results in the health process.
Referanslar
American Cancer Society (ACS). Key statistics for prostate cancer. https://www.cancer.org/cancer/prostate-cancer/about/key-statistics.html (Erişim tarihi: 12/12/2023).
World Health Organization (WHOa). International agency for reasearch on cancer [Internet]. https://gco.iarc.fr/today/online-analysispie?v=2020&mode=cancer&mode_population=continents&population=900&populations=900&key=total&sex=1&cancer=39&type=0&statistic=5&prevalence=0&population_group=0&ages_group%5B%5D=0&ages_group%5B%5D=17&nb_items=7&group_cancer=1&include_nmsc=1&include_nmsc_other=1&half_pie=0&donut=0 (Erişim tarihi 15/12/2023).
Türkiye Halk Sağlığı Kurumu Kanser Dairesi Başkanlığı (THSKKDB). Türkiye kanser istatistikleri 2017. https://hsgm.saglik.gov.tr/depo/birimler/kanser-db/Dokumanlar/Istatistikler/Kanser_Rapor_2018.pdf (Erişim tarihi: 12/12/2023).
World Health Organization (WHOb). International agency for reasearch on cancer [Internet].https://gco.iarc.fr/tomorrow/en/dataviz/isotype?cancers=27&single_unit=50000&sexes=1&types=0 (Erişim tarihi: 22/12/2023).
Cackowski FC, Mahal B, Heath EI, ve ark. Evolution of disparities in prostate cancer treatment: is this a new normal? Am Soc Clin Oncol Educ Book. 2021; 41, e203-e214.
Rao AG, Dkhar W, Sharath S, ve ark. Knowledge, awareness and practice towards screening for prostate cancer: a systematic review and meta-analysis. Ethiop J Health Sci. 2023; 33(3):547–554.
Owoo B, Ninnoni JP, Ampofo EA, ve ark. Challenges encountered by family caregivers of prostate cancer patients in Cape Coast, Ghana: a descriptive phenomenological study. BMC Palliat Care. 2022; 21(1):1-11.
Ng KL. The etiology of prostate cancer. In: Bott SRJ, Ng KL, eds. Prostate Cancer. 1st ed. Brisbane (AU): Exon Publications, 2021. Chapter 2, p.17-27.
Middleton R, Thomas P. Nursing care of men with reproductive system and breast disorders. In: LeMone P, Burke KM, Bauldoff, G, ve ark., eds. Medical Surgical Nursing Critical Thinking For Person Centred Care. 3rd ed. Australia: Australian Edition, Pearson Australia Group, 2017, volume 3, p.1757-1783. ISBN: 9781488611766.
Lutz A. Male reproductive problems, In: Harding MM, Kwong, J, Roberts D, ve ark, eds. Lewis’s Medical-Surgical Nursing Assesment And Management Of Clinical Problems. 11th ed. Missouri: Elsevier, 2020, p.4724-4818. ISBN: 978-0-323-55149-6.
Xu X, Kharazmi E, Tian Y, ve ark. Risk of prostate cancer in relatives of prostate cancer patients in Sweden: A nationwide cohort study. PLoS Med. 2021; 18(6):e1003616.
Page EC, Bancroft E, Brook M, ve ark. Interim results from the IMPACT study: evidence for prostate-specific antigen screening in BRCA2 mutation carriers. Eur Urol. 2019; 76: 831.
Rani A, Dasgupta P, Murphy JJ. Prostate cancer: the role of inflammation and chemokines. Am J Pathol. 2019;189(11):2119–37.
Pernar CH, Ebot EM, Wilson KM, ve ark. The epidemiology of prostate cancer. Cold Spring Harb Perspect Med. 2018; 8(12): a030361.
Brookman-May SD, Campi R, Henriquez JDS, ve ark. Latest evidence on the impact of smoking, sports, and sexual activity as modifiable lifestyle risk factors for prostate cancer ıncidence, recurrence, and progression: a systematic review of the literature by the European association of urology section of oncological urology (ESOU). Eur Urol Focus. 2019; 5(5):756-787.
Smith LA, O’Flanagan CH, Bowers LW, ve ark. Translating mechanism-based strategies to break the obesity-cancer link: a narrative review. J Acad Nutr Diet. 2019; 118(4):652–67.
Trudeau K, Rousseau MC, Parent M. Extent of food processing and risk of prostate cancer: the proteus study in Montreal, Canada. Nutrients. 2020; 12(3):637
Langlais CS, Graff RE, Van Blarigan EL, ve ark. Post-diagnostic dietary and lifestyle factors and prostate cancer recurrence, progression, and mortality. Curr Oncol Rep. 2021; 23(3):1-20.
Rowles III JL, Ranard KM, Applegate CC, ve ark. Processed and raw tomato consumption and risk of prostate cancer: a systematic review and dose-response meta-analysis. Prostate Cancer Prostatic Dis. 2018; 21(3):319-336.
Applegate CC, Rowles JL, Ranard KM, ve ark. Soy consumption and the risk of prostate cancer: an updated systematic review and meta-analysis. Nutrients. 2018; 10(1):40.
Ju-Kun S, ve ark. Association between CD exposure and risk of prostate cancer: a prisma compliant systematic review and meta-analysis. Medicine (Baltimore). 2016; 95(6): e2708.
Burns JA, Weiner AB, Catalona WJ, ve ark. Inflammatory bowel disease and the risk of prostate cancer, Eur Urol. 2019; 75(5):846-852.
Mottet N, Cornford P, van den Bergh, RCN, ve ark. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2022 Update. EAU-EANM-ESTRO-ESUR-ISUP_SIOG-Guidelines-on-Prostate-Cancer-2022_2022-04-25-063938_yfos.pdf (d56bochluxqnz.cloudfront.net) (Erişim tarihi: 22/12/2023).
Rawla P. Epidemiology of prostate cancer, World J Oncol. 2019; 10(2):63-89.
Gavin AT, Drummond FJ, Donnelly C, ve ark. Patient reported 'ever had' and 'current' long-term physical symptoms after prostate cancer treatments, BJU Int. 2015; 116(3):397-406.
Downing A, Wright P, Hounsome L, ve ark. Quality of life in men living with advanced and localised prostate cancer in the UK: a population based study. Lancet Oncol. 2019; 20(3):436-447.
Colloca G, Colloca P. The effects of social support on health-related quality of life of patients with metastatic prostate cancer. J Cancer Educ. 2016; 31(2):244-52.
Özbaş A. Erkek üreme sistemi hastalıkları ve bakımı. İçinde: Akyolcu N, Kanan N, Aksoy G, editörler. Cerrahi Hemşireliği II. 2. Baskı. İstanbul: Nobel Tıp Kitabevi, 2018, p.380-432. ISBN:978-605-335-343-0.
Toplutas KN, Kabasakal L, Ekmekçioğlu O. Prostat kanserinde tedavi yanıtının değerlendirilmesinde Ga-68 PSMA PET/BT: Ga-68 PSMA PET/CT in the evaluation of treatment response in prostate cancer. Nucl Med Semin. 2021; 7(2):246-251.
Buyyounouski MK, Choyke PL, McKenney JK, ve ark. Prostate cancer–major changes in the American joint committee on cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017; 67(3):245-253.
Mohanty SK, Lobo A, Cheng L. The 2022 revision of the World Health Organization classification of tumors of the urinary system and male genital organs: advances and challenges. Hum Pathol. 2023; 136:123-143.
Nolsøe AB, Jensen CFS, Østergren PB, ve ark. Neglected side effects to curative prostate cancer treatments, Int J Impot Res. 2021; 33(4):428-438.
Edmunds K, Tuffaha H, Galvão DA, ve ark. Incidence of the adverse effects of androgen deprivation therapy for prostate cancer: a systematic literature review. Support Care Cancer. 2020; 28(5):2079-2093.
Appleyard SE, Larkin MJW, Stewart EM, ve ark. Digital medicine in men with advanced prostate cancer–a feasibility study of electronic patient reported outcomes in patients on systemic treatment, Clinical Oncology. 2021;33(12):751-760.
Lee HH, Park S, Joung JY, ve ark. How does androgen deprivation therapy affect mental health including cognitive dysfunction in patients with prostate cancer? World J Mens Health. 2021; 39(4):598-605.
Prettyman J, Engel L, Boldt-Houle DM, ve ark. Personalizing treatment in the delivery of care by nurses to patients with prostate cancer. Urol Nurs. 2019; 39(2):83-99.
Coughlin GD, Yaxley JW, Chambers SK, ve ark. Robot-assisted laparoscopic prostatectomy versus open radical retropubic prostatectomy: 24-month outcomes from a randomised controlled study. Lancet Oncol. 2018; 19(8):1051-1060.
Fang K, Song P, Zhang J, ve ark. The impact of palliative transurethral resection of the prostate on the prognosis of patients with bladder outlet obstruction and metastatic prostate cancer: a population-matched study. Front Surg. 2021; 8:726534.
Strouthos I, Chatzikonstantinou G, Zamboglou N, ve ark. Combined high dose rate brachytherapy and external beam radiotherapy for clinically localised prostate cancer. Radiother Oncol. 2018; 128(2):301-307.
Keske M, Canda AE. Prostat kanser lokalize hastalıkta tedavi. İçinde: Yaman MÖ, Kadıoğlu A, Taşçı Aİ, editörler. Güncel Üroloji. 2. Baskı. İstanbul: Nobel Tıp Kitabevleri, 2018, bölüm 50, p.622-628. ISBN: 978-605-68063-1-5
Hışır D, Ekinci M, Derya İÖ. Hedefe yönelik tedavide güncel yaklaşımlar: lütesyum 177 ile işaretli radyofarmasötikler Journal of Faculty of Pharmacy of Ankara University. 2022; 46 (1): 209-230.
National Comprehensive Cancer Network (NCCN). Clinical practice guidelines in oncology: prostate cancer. versiyon 1.2023. https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf (Erişim tarihi:19/12/2023).
Erturhan S. Kastrasyon rezistan prostat kanserinde tedavi alternatifleri. İçinde: Yaman MÖ, Kadıoğlu A, Taşçı Aİ, editörler. Güncel Üroloji. 2. Baskı. İstanbul: Nobel Tıp Kitabevleri, 2018, Bölüm 52, p.641-647. ISBN: 978-605-68063-1-5.
Selcuk NA, Yencilek F. Ra-223 Alpha treatment in prostate cancer/prostat kanserinde Ra-223 alfa tedavi. Nucl Med Semin. 2018; 4(3):240-245.
Smoleń E, Słysz M, Hombek K, ve ark. Health self-assessment and functioning of people with cancer. Nursing And Public Health. 2020; 10(1):27–34.
Johnson M, Perry-Philo D. Nursing care of male patients with genitourinary disorders. In: Williams LD, Hopper PD, eds. Understanding Medical Surgical Nursing. 5th ed. Philadelphia: F.A. Davis Company, 2015, chapter 43, p.1004-1023. ISBN 13: 978-0-8036-4068-9.
Cancer Council Australia. Understanding prostate cancer a guide for people with cancer, their families and friends, Sydney. ISBN 978 1 925651 83 6. https://www.cancer.org.au/assets/pdf/understanding-prostate-cancer-booklet Erişim tarihi: 14/01/2024.
Lowrance W, Breau R, Chou R, ve ark. Updates to advanced prostate cancer: AUA/SUO guideline (2023). J Urol. 2023;209(6):1082-1090.
